摘要
目的:探讨西妥昔单抗联合FOLFIRI治疗转移性结肠癌的效果和不良反应。方法:收治转移性结肠腺癌患者10例,给予西妥昔单抗联合FOLFIRI治疗。结果:有效率20%,疾病控制率80%。中位疾病进展时间(TTP)9.7周,中位生存时间(MST)42周。1例出现严重过敏反应,10例患者出现痤疮样皮疹。结论:西妥昔单抗联合FOLFIRI治疗转移性结肠癌有更高的反应率。
Objective:To investigate the curative effect and adverse reactions of cetuximab combined with FOLFIRI in thetreatment of metastatic colorectal cancer.Methods:10 cases of patients with metastatic colorectal cancer were treated withcetuximab combined with FOLFIRI.Results:The effective rate was 20%,and the disease control rate was 80%.The median time oftumor progression was 9.7 weeks and the median survival time (MST) was 42 weeks.1 cases had severe allergic reaction,10 casesof patients had acne-like rash.Conclusion:Cetuximab combined with FOLFIRI in the treatment of metastatic colorectal cancerhad higher response rate.
作者
刘瑾
Liu Jin(Department of Oncology,the First People's Hospital of Qujing City,Yunnan Province 655000)
出处
《中国社区医师》
2016年第5期48-49,共2页
Chinese Community Doctors